Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
IMCR similar filings
- 28 Feb 24 Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- 2 Feb 24 Immunocore Prices Upsized Convertible Senior Notes Offering
- 29 Jan 24 Immunocore Announces Proposed Convertible Senior Notes Offering
- 5 Jan 24 Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
- 2 Jan 24 Regulation FD Disclosure
Filing view
External links
Exhibit 99.3
5 1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world.; 3. Program is not HLA restricted (ie. universal for all populations) Leading bispecific TCR pipeline Oncology Infectious Autoimmune Candidate Target (HLA type) gp100 (A02) Indication Uveal (ocular) melanoma IND-enabling Phase 1 Phase 2 Phase 3 Approved Catalyst Adjuvant uveal (ocular) melanoma ATOM sponsore d by Phase 3 Start | 2H24 2L+ cutaneous melanoma TEBE-AM Phase 2 Data | 4Q24 IMC-F106C PRAME (A02) 1L cutaneous melanoma PRISM-MEL-301 Phase 3 Start | 1Q24 2L+ cutaneous melanoma Phase 1 Clinical Data 2Q24 – 4Q2024 PRR ovarian1 2L+ NSCLC Advanced endometrial Multiple solid tumors Mono. & combina tion arms IMC-P115C PRAME-HLE (A02) Multiple solid tumors IND/CTA | Mid-24 IMC-T119C PRAME (A24) Multiple solid tumors IND/CTA | 4Q24 IMC-R117C PIWIL1 (A02) Colorectal, gastric, pancreatic Phase 1 Start | 2024 IMC-M113V2 Gag (A02) Human Immunodeficiency Virus (HIV) MAD Data | 2H24 IMC-I109V Envelope (A02) Hepatitis B Virus (HBV) IMC-S118AI PPI (A02) Type 1 Diabetes Undisclosed (universal)3 Dermatology New candidate added to pipeline January 2024.